Roche's Avastin-Xeloda combo extends breast cancer survival; Genzyme sees faster rollouts coming in China;

@FiercePharma: ICYMI yesterday: Overseas limits on J&J's Olysio use might signal trouble back home. Item | More | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Roche ($RHHBY) said its cancer drug Avastin, when combined with its chemotherapy Xeloda, helped women with HER2-negative breast cancer live longer than those treated with Avastin alone. Report

> Genzyme CEO David Meeker says it expects to roll out new drugs in China at a faster pace in the future because the country's understanding of rare diseases has grown. Report

> Valeant Pharmaceuticals ($VRX) brought another representative of top shareholder ValueAct, Jeffrey Ubben, onto its board to replace the departed Mason Morfit. Report

> MannKind ($MNKD) said its Afrezza marketing deal with Sanofi ($SNY) has closed, putting the smaller company in line for a $150 million up-front payment. Release

> Bridgewater, NJ-based Amneal Pharmaceuticals said it would expand its sales and distribution center in Kentucky. Report

Medical Device News

@FierceMedDev: NIH launches study of 'exceptional responders' to cancer therapies. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Titan Pharma trial of implant for addicts on track. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: 3-D printed blood vessels? Check. On to the 3-D printed kidneys, say researchers at Harvard. More from MIT Technology Review | Follow @EmilyWFierce

> At least 23 digital health apps clear FDA this year. Item

> Court rules that Boston Scientific owes inventor of pacemaker $309M. Report

Biotech News

@FierceBiotech: VentiRx banks $50M as it ramps up immuno-oncology research efforts in Seattle. Report | Follow @FierceBiotech

@JohnCFierce: Adaptimmune gathers $104M to fuel hot immuno-oncology tech race - TCRs/CAR-T. More | Follow @JohnCFierce

@DamianFierce: Here's the official Kadmon release on the Waksal swap, replete with semi-acknowledgement of IPO plot. Release | Follow @DamianFierce

@EmilyMFierce: This on misses the mark in so many ways and lacks a basic understanding of drug development. Article | Follow @EmilyMFierce

> Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet. News

> Valeant talks up the billion-dollar potential of its Phase III eye drug. Story

> Novartis' blockbuster hopeful scores a win in psoriatic arthritis. Article

Vaccines News

> Inovio joins Ebola fight while WHO says a vaccine could be ready by year's end. Story

> CureVac inks lung cancer vaccine deal with Boehringer for up to $600M. Report

> U.K. panel under pressure to extend use of Merck's Gardasil to boys. Article

> Pharmacies continue push to lower barriers to seasonal flu vaccination. Report

> Accidental poliovirus dump adds to GSK's production woes. More

Pharma Manufacturing News

> IGI jumps into sterile injectable biz with $9.5M deal with AstraZeneca. More

> Report: 'Green' manufacturing needed to save money as well as the environment. Item

> Sanofi expands production at Merial plant in Brazil. More

> Alkermes manufacturing technology key to Acorda buyout of Civitas. Article

> Impax settles securities suit tied to its manufacturing issues. Story

And Finally... The rate of growth in diabetes in the U.S. appears to have plateaued. Report (sub. req.)